Mineralys Therapeutics is focused on developing targeted therapies for hypertension and cardio-renal-metabolic syndrome, particularly through the use of lorundrostat, a selective aldosterone synthase inhibitor
Mineralys Therapeutics is focused on developing targeted therapies for hypertension and cardio-renal-metabolic syndrome, particularly through the use of lorundrostat, a selective aldosterone synthase inhibitor.